Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRI Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
NCT04165941Phase 1Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2020
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma multiforme (GBM), sponsored by University of Alabama at Birmingham. Primary endpoint: Highest safe dose frequency or maximally planned dose at 12 weeks. Started Feb 2020; status: active, not recruiting.
02
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04165941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165941.